I am very excited to inform you all of the response i have from management in regards to the new FDA rule changes.
This is a very very very good response and has me buzzing on top of the already busy 2017 H1 in terms of material news flow.
"In terms of what I can tell you at this stage, this definitely has the potential to be beneficial for Neurotech in seeking approval for Mente Autism, and we’ll provide more information to the market on this once we have clarification from our advisor for registration in the US, as well as the FDA itself."
European sales coming in left right and center very soon mixed with a very tight register and a accommodating sub sector (medtech) we are going to be firing on all cylinders in the very near future sooooo undervalued.
IMO stock of 2017 is right here and would not be surprised to see a 7-Disallowed from this level in calender year 2017 alone particularly H1.
All the best
Cheers bonkers
NTI Price at posting:
37.0¢ Sentiment: Buy Disclosure: Held
